Patents by Inventor Philip Albert Carpino

Philip Albert Carpino has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Dipeptide derivatives
    Publication number: 20020042415
    Abstract: This invention is directed to compounds of the formula 1
    Type: Application
    Filed: March 30, 2001
    Publication date: April 11, 2002
    Inventors: Philip Albert Carpino, David Andrew Griffith, Bruce Allen Lefker
  • Dipeptide derivatives
    Publication number: 20020002165
    Abstract: This invention is directed to compounds of the formula 1
    Type: Application
    Filed: March 30, 2001
    Publication date: January 3, 2002
    Inventors: Philip Albert Carpino, David Andrew Griffith, Bruce Allen Lefker
  • Dipeptide derivatives
    Publication number: 20010041703
    Abstract: This invention is directed to compounds of the formula 1
    Type: Application
    Filed: March 30, 2001
    Publication date: November 15, 2001
    Inventors: Philip Albert Carpino, David Andrew Griffith, Bruce Allen Lefker
  • Tartrate salt of a substituded dipeptide as growth hormone secretagogue
    Publication number: 20010016570
    Abstract: This invention is directed to the (L)-tartaric acid salt of 2-amino-N-{1 -(R)-(2,4-difluoro-benzyloxymethyl)-2-oxo-2-[3-oxo-3a-(R)-pyridin-2-ylmethyl-2-(2,2,2-trifluoroethyl)-2,3,3a,4,6,7-hexahydro-pyrazolo[4,3-c]pyridin-5-yl]-ethyl}-2-methyl-propionamide which is a growth hormone secretagogue and as such is useful for increasing the level of endogenous growth hormone. In another aspect, this invention provides certain intermediates which are useful in the synthesis of the foregoing compound. The (L)-tartaric acid salt of the compound of this invention is useful for the treatment and/or prevention of osteoporosis, insulin resistance and other conditions or diseases associated with growth hormone deficiency.
    Type: Application
    Filed: December 11, 2000
    Publication date: August 23, 2001
    Inventors: Philip Albert Carpino, Paul Andrew Dasilva-Jardine, Bruce Allen Lefker, Jerry Anthony Murry
  • Dipeptide derivatives as growth hormone secretagogues
    Patent number: 6251902
    Abstract: This invention is directed to compounds of the formula and the pharmaceutically-acceptable salts thereof, where the substituents are as defined in the Specification, which are growth hormone secretogogues and which increase the level of endogenous growth hormone. The compounds of this invention are useful for the treatment and prevention of osteoporosis and/or frailty, congestive heart failure, frailty associated with aging, obesity; accelerating bone fracture repair, attenuating protein catabolic response after a major operation, reducing cachexia and protein loss due to chronic illness, accelerating wound healing, or accelerating the recovery of burn patients or patients having undergone major surgery; improving muscle strength, mobility, maintenance of skin thickness, metabolic homeostasis or renal homeostasis.
    Type: Grant
    Filed: September 8, 1999
    Date of Patent: June 26, 2001
    Assignee: Pfizer Inc.
    Inventors: Philip Albert Carpino, David Andrew Griffith, Bruce Allen Lefker
  • Tartrate salt of a substituted dipeptide as growth hormone secretagogue
    Patent number: 6248717
    Abstract: This invention is directed to the (L)-tartaric acid salt of 2-amino-N-{1-(2,4-difluoro-benzyloxymethyl)-2-oxo-2-[3-oxo-3a-pyridin-2-ylmethyl-2-(2,2,2-trifluoro-ethyl)-2,3,3a,4,6,7-hexahydro-pyrazolo{4,3-c}pyridin-5-yl]-ethyl]-2-methyl-propionamide which is a growth hormone secretagogue and as such is useful for increasing the level of endogenous growth hormone. In another aspect this invention provides certain intermediates which are useful in the synthesis of the foregoing compound. The (L)-tartaric acid salt of the compound of this invention is useful in the treatment and/or prevention of osteoporosis, insulin resistance and other conditions or diseases associated with growth hormone deficiency. The (L)-tartaric acid salt of the compound of the present invention is also useful in treating osteoporosis when used in combination with: a bisphosphonate compound; estrogen, Premarin, and optionally progesterone; an estrogen agonist or antagonist; or calcitonin.
    Type: Grant
    Filed: September 7, 1999
    Date of Patent: June 19, 2001
    Assignee: Pfizer Inc.
    Inventors: Philip Albert Carpino, Paul Andrew Dasilva-Jardine, Bruce Allen Lefker, Jerry Anthony Murry